The Effects of the Endocrine System on Endometrial Cancer (Ghrelin)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by Queensland Centre for Gynaecological Cancer.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Greenslopes Private Hospital
The University of Queensland
Sullivan and Nicolaides Pathology
Information provided by:
Queensland Centre for Gynaecological Cancer
ClinicalTrials.gov Identifier:
NCT01075386
First received: February 23, 2010
Last updated: June 12, 2012
Last verified: June 2012
  Purpose

Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.


Condition
Endometrial Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer

Resource links provided by NLM:


Further study details as provided by Queensland Centre for Gynaecological Cancer:

Biospecimen Retention:   Samples Without DNA

Endometrial tissue


Estimated Enrollment: 80
Study Start Date: October 2009
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Grade 2
Patients with Endometrial cancer of Grade 1 differentiation
Benign
Patients without endometrial cancer
Grade 1
Patients with Endometrial cancer of Grade 2 differentiation
Grade 3
Patients with Endometrial cancer of Grade 3 differentiation

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with endometrial cancer and patients who are having a hysterectomy for non-cancerous conditions such as fibroids, chronic pelvis pain or abnormal uterine bleeding are eligible for the study

Criteria

Inclusion Criteria:

  • women aged 18 years or older
  • having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding
  • have provided informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01075386

Contacts
Contact: Trudi Cattley trudi_cattley@health.qld.gov.au

Locations
Australia, Queensland
Greenslopes Private Hospital Recruiting
Greenslopes, Queensland, Australia, 4120
Contact: Fiona Menzies    3646 4467    fiona_menzies@health.qld.gov.au   
Contact: Trudi Cattley    3646 0447    trudi_cattley@health.qld.gov.au   
Principal Investigator: Andreas Obermair         
Principal Investigator: Chen Chen         
Sponsors and Collaborators
Queensland Centre for Gynaecological Cancer
Greenslopes Private Hospital
The University of Queensland
Sullivan and Nicolaides Pathology
Investigators
Study Chair: Chen Chen, MD PhD The University of Queensland
  More Information

No publications provided

Responsible Party: Professor Chen Chen, University of Queensland
ClinicalTrials.gov Identifier: NCT01075386     History of Changes
Other Study ID Numbers: Endo01
Study First Received: February 23, 2010
Last Updated: June 12, 2012
Health Authority: Australia: National Health and Medical Research Council
Australia: Department of Health and Ageing Therapeutic Goods Administration
Australia: Human Research Ethics Committee

Keywords provided by Queensland Centre for Gynaecological Cancer:
Hysterectomy
Endometrial cancer
Benign
Endocrine system
Tissue collection

Additional relevant MeSH terms:
Endometrial Neoplasms
Sarcoma, Endometrial Stromal
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Neoplasms, Complex and Mixed
Neoplasms by Histologic Type
Sarcoma
Neoplasms, Connective and Soft Tissue
Endometrial Stromal Tumors

ClinicalTrials.gov processed this record on July 26, 2014